Fabtech Technologies Limited (NSE: FABTECH, BSE: 544558) is a Mumbai, Maharashtra-based company in the Pharmaceutical Manufacturing Equipment industry. With a market capitalisation of ₹620 Cr, it ranks #1,873 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹134.90 (as of 19 Nov 2026), the share price is 47.5% below its 52-week high of ₹256.95 and 17.2% above its 52-week low of ₹115.10. The share price is down 42.4% over one year and down 8.3% over three months.
| Current Price | ₹134.90 |
|---|---|
| Market Cap | ₹620 Cr |
| NSE Symbol | FABTECH |
| BSE Code | 544558 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical Manufacturing Equipment |
| P/E Ratio | 14.2 |
| Return on Equity | 9.14% |
| Return on Assets | 3.34% |
| 52-Week Range | ₹115.10 – ₹256.95 |
| 1-Year Price Change | -42.4% |
| 3-Month Price Change | -8.3% |
| Beta (1Y) | 0.34 |
| Dividend Yield | 0.42% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.fabtechnologies.com |
| Revenue | ₹92 Cr |
|---|---|
| Net Profit | ₹15 Cr |
| Net Margin | 16.3% |
| EPS (Basic) | ₹3.38 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Fabtech Technologies Limited reported revenue of ₹92 Cr in Q2 FY27, down 24.2% from ₹121 Cr in Q2 FY26 and up 22.8% from ₹75 Cr in Q1 FY27. It posted a net profit of ₹15 Cr for the quarter, against a net profit of ₹28 Cr in Q2 FY26 (down 46.6%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹63 Cr (Q3 FY26) to ₹159 Cr (Q4 FY26). The company reported a net loss in 2 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹92 Cr | ₹15 Cr | 16.3% |
| Q1 FY27 | ₹75 Cr | ₹4 Cr | 5.6% |
| Q4 FY26 | ₹159 Cr | ₹22 Cr | 13.9% |
| Q3 FY26 | ₹63 Cr | −₹6 Cr | −9.1% |
| Q2 FY26 | ₹121 Cr | ₹28 Cr | 23.1% |
| Q1 FY26 | ₹68 Cr | −₹6 Cr | −9.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 69.03% of Fabtech Technologies Limited's shares as of Sept 2026, against 68.94% in Oct 2025 (+0.09 percentage points). Delivery averaged 48.5% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Fabtech Technologies Limited operates as a biopharma engineering company that provides aseptic manufacturing facilities internationally. The company offers designing, engineering, procurement, installation, and testing of pharmaceutical equipment. It serves pharmaceuticals, biotech, and healthcare companies. The company was founded in 2001 and is based in Mumbai, India.
1. Surgical & Medical Equipment-This segment engages in the provision of turnkey project solutions to pharmaceuticals and allied industries. 2. NA-NA 3. NA-NA 4. NA-NA
1. Surgical & Medical Equipment-100%
Fabtech Technologies Limited is trading at ₹134.90, with a market capitalisation of ₹620 Cr.
Fabtech Technologies Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical Manufacturing Equipment).
Fabtech Technologies Limited has a P/E of 14.2 and a return on equity of 9.14%.
Fabtech Technologies Limited is listed on the NSE under the symbol FABTECH and on the BSE under the scrip code 544558.
Fabtech Technologies Limited's share price is down 42.4% over one year and down 8.3% over three months. Its 52-week range is ₹115.10 to ₹256.95.
In Q2 FY27, Fabtech Technologies Limited reported revenue of ₹92 Cr and net profit of ₹15 Cr, with basic EPS of ₹3.38 (consolidated, parsed from the company's exchange filing).
Fabtech Technologies Limited reported revenue of ₹92 Cr in Q2 FY27, down 24.2% from ₹121 Cr in Q2 FY26 and up 22.8% from ₹75 Cr in Q1 FY27.
Promoters held 69.03% of Fabtech Technologies Limited's shares as of Sept 2026, against 68.94% in Oct 2025 (+0.09 percentage points).
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.